Drug and Alcohol Dependence
Volume 65, Issue 3 , Pages 209-220 , 1 February 2002

GABAB receptor agonists for the treatment of drug addiction: a review of recent findings

  • Michael S. Cousins

      Affiliations

    • Department of Psychiatry, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-77-37020084; fax: +1-77-37026454
    • ,
  • David C.S. Roberts

      Affiliations

    • Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
    • ,
  • Harriet de Wit

      Affiliations

    • Department of Psychiatry, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA

Received 14 March 2000 ,Revised 7 December 2000 ,Accepted 9 January 2001.

References 

  1. Addolarato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II. Preliminary clinical evidence. Alchol. Clin. Exp. Res. 2000;24(1):67–71
  2. Agmo A, Giordano M. The locomotor-reducing effects of GABAergic drugs do not depend on the GABAA receptor. Psychopharmacology (Berlin). 1985;87(1):51–54
  3. al-Dahan MI, Tehrani MH, Thalmann RH. Effect of 2-hydroxy-saclofen, an antagonist of GABAB action, upon the binding of baclofen and other receptor ligands in rat cerebrum. Brain Res. 1990;526(2):308–312
  4. Ashby CR, Rohatgi R, Ngosuwan J, Borda T, Gerasimov MR, Morgan AB, et al. Implication of the GABA(B) receptor in gamma vinyl-GABA's inhibition of cocaine-induced increases in nucleus accumbens dopamine. Synapse. 1999;31:151–153
  5. Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit. Rev. Neurobiol. 1998;12(1-2):37–67
  6. Bartholini G. GABA receptor agonists: pharmacological spectrum and therapeutic actions. Med. Res. Rev. 1985;5(1):55–75
  7. Bertolucci-D'Angio M, Serrano A, Scatton B. Mesocorticolimbic dopaminergic systems and emotional states. J. Neurosci. Methods. 1990;34(1–3):135–142
  8. Bolser DC, Blythin DJ, Chapman RW, Egan RW, Hey JA, Rizzo C, et al. The pharmacology of SCH 50911: a novel, orally-active GABA-beta receptor antagonist. J. Pharmacol. Exp. Ther. 1995;274(3):1393–1398
  9. Bowery NG, Hudson AL, Price GW. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience. 1987;20:365–383
  10. Brazell MP, Mitchell SN, Joseph MH, Gray JA. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudateputamen. Neuropharmacology. 1990;29(12):1177–1185
  11. Brebner K, Froesti W, Andrews M, Phelan R, Roberts DCS. The GABAB agonist CGP 44532 decreases cocaine self-administration in rats: Demonstration using a progressive ratio and a discrete trials procedure. Neuropharmacology. 1999;38(11):1797–1804
  12. Brebner K, Phelan R, Roberts DCS. Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology. 2000;148(3):314–321
  13. Brebner, K., Phelan, R., Roberts, D.C.S., 2000b. Intra-VTA baclofen attenuates cocaine self-administration on a progressive ratio schedule of reinforcement. Pharmacol. Biochem. Behav., in press.
  14. Breslow MF, Fankhauser MP, Potter RL, Meredith KE, Misiaszek J, Hope DG. Role of gamma-aminobutyric acid in antipanic drug efficacy. Am. J. Psychiatry. 1989;146(3):353–356
  15. Brose N, O'Neill RD, Boutelle MG, Anderson SM, Fillenz M. Effects of an anxiogenic benzodiazepine receptor ligand on motor activity and dopamine release in nucleus accumbens and striatum in the rat. J. Neurosci. 1987;7(9):2917–2926
  16. Buckett WR. The influence of a GABA transaminase inhibitor, gamma-vinyl GABA, on voluntary morphine consumption in the rat. Psychopharmacology (Berlin). 1981;75(2):214–216
  17. Caddick SJ, Stanford IM, Chad JE. 2-Hydroxy-saclofen causes a phaclofenreversible reduction in population spike amplitude in the rat hippocampal slice. Eur. J. Pharmacol. 1995;274(1–3):41–46
  18. Campbell UC, Lac ST, Carroll ME. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology (Berlin). 1999;143(2):209–214
  19. Caskey NH, Jarvik ME, Wirshing WC. The effects of dopaminergic D2 stimulation and blockade on smoking behavior. Exp. Clin. Psychopharmacol. 1999;7(1):72–78
  20. Chu DCM, Albin RL, Young AB, Penney JB. Distribution and kinetics of GABAB binding sites in rat central nervous system: a quantitative autoradiographic study. Neuroscience. 1990;34:341–357
  21. Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I. Preclinical evidence. Alcohol. Clin. Exp. Res. 2000;24(1):58–66
  22. Cousins MS, Stamat HM, de Wit H. Effects of d-amphetamine and the GABA(B) receptor agonist baclofen on cigarette smoking and nicotine craving. College on Problems of Drug Dependence 62nd Annual Meeting. 2000;32:
  23. Cousins, M.S., Stamat, H.M., de Wit, H., 2000b. Single doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacol., under review.
  24. Daoust M, Saligaut C, Lhuintre JP, Moore N, Flipo JL, Boismare F. GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats. Alcohol. 1987;4(6):469–472
  25. Dawe S, Gerada C, Russell MA, Gray JA. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berlin). 1995;117(1):110–115
  26. de Wit H, Griffiths R. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend. 1991;28(1):83–111
  27. Dewey SL, Chaurasia CS, Chen CE, Volkow ND, Clarkson FA, Porter SP, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse. 1997;25(4):393–398
  28. Dewey SL, Morgan AE, Ashby CRJ, Horan B, Kushner SA, Logan J, et al. A novel strategy for the treatment of cocaine addiction. Synapse. 1998;30(2):119–129
  29. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CRJ. A pharmacologic strategy for the treatment of nicotine addiction. Synapse. 1999;31(1):76–86
  30. Gerasimov MR, Dewey SL. Gamma-vinyl gamma-aminobutyric acid attenuates the synergistic elevations of nucleus accumbens dopamine produced by a cocaine/heroin (speedball) challenge [In Process Citation]. Eur. J. Pharmacol. 1999;380(1):1–4
  31. Gerasimov MR, Ashby CR, Gardner EL, Mills MJ, Brodie JD, Dewey SL. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse. 1999;34(1):11–19
  32. Gong W, Neill DB, Justice JBJ. GABAergic modulation of ventral pallidal dopamine release studied by in vivo microdialysis in the freely moving rat. Synapse. 1998;29(4):406–412
  33. Grech DM, Balster RL. Pentobarbital-like discriminative stimulus effects of direct GABA agonists in rats. Psychopharmacology (Berlin). 1993;110(3):295–301
  34. Grech DM, Balster RL. The discriminative stimulus effects of muscimol in rats. Psychopharmacology (Berlin). 1997;129(4):339–347
  35. Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV. Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology (Berlin). 1991;103(2):154–161
  36. Gudeman D, Shoptaw S, Majewska D, Scherf S, Yeats D, Ling W. Preliminary report of baclofen as a cocaine craving medication. NIDA Res. Monogr. 1996;174:183
  37. Guitart X, Lumeng L, Li TK, Nestler EJ. Alcohol-preferring and nonpreferring rats display different levels of neurofilament proteins in the ventral tegmental area. Alcohol. Clin. Exp. Res. 1993;17(3):580–585
  38. Hoebel BG, Hernandez L, Mark GP, Pothos E. Microdialysis in the study of psychostimulants and the neural substrate for reinforcement: focus on dopamine and serotonin. NIDA Res. Monogr. 1992;124:1–34
  39. Imperato A, Mulas A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur. J. Pharmacol. 1986;132(2-3):337–338
  40. Johanson CE. Why publish three negative articles on carbamazepine as a medication for the treatment of cocaine dependence?. Drug Alcohol Depend. 1995;38(3):201–202
  41. Jori A, Bemardi D, Pugliatti C, Garattini S. Strain differences in the metabolism of imipramine by rat. Biochem. Pharmacol. 1970;19(4):1315–1321
  42. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J. Neurochem. 1977;29:787–802
  43. Kacew S, Festing MF. Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. J. Toxicol. Environ. Health. 1996;47(1):1–30
  44. Knapp CM, Cottam N, Dewey SL, Kometsky C. The GABA transaminase inhibitor, vigabatrin, reduces responding for heroin self-administration. Soc. Neurosci. Abstr. 1999;25:558
  45. Koob GF, Nestler EJ. The neurobiology of drug addiction. J. Neuropsychiatry Clin. Neurosci. 1997;9(3):482–497
  46. Krupitski EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko A, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend. 1993;33(2):157–163
  47. Kushner SA, Dewey SL, Kornetsky C. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berlin). 1997;133(4):383–388
  48. Kushner SA, Dewey SL, Kometsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 1999;290(2):797–802
  49. Lacey MG, Mercuri NB, North RA. On the potassium conductance increase activated by GABA-B and dopamine D-2 receptors in rat substantia nigra neurones. J. Physiol. 1988;401:401–435
  50. Ling W, Shoptaw S, Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology. 1998;18(5):403–404
  51. Markowitz JS, Finkenbine R, Myrick H, King L, Carson WH. Gabapentin abuse in a cocaine user: implications for treatment?. J. Clin. Psychopharmacol. 1997;17(5):423–424
  52. Marshall DL, Redfem PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem. 1997;68(4):1511–1519
  53. McEvoy JP, Freudenreich O, Levin ED, Rose JE. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berlin). 1995;119(1):124–126
  54. McManus DJ, Greenshaw AJ. Differential effects of chronic antidepressants in behavioural tests of beta-adrenergic and GABAB receptor function. Psychopharmacology (Berlin). 1991;103(2):204–208
  55. Morgan AE, Dewey SL. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse. 1998;28(1):60–65
  56. Myrick H, Henderson S, Brady KT. Divalproex in the treatment of cocaine dependence. NIDA Res. Monogr. 1998;179:295
  57. Myrick H, Henderson S, Brady KT. Gabapentin treatment of cocaine dependence. College on Problems of Drug Dependence Annual Meeting. 1999;61:112
  58. Palacios JM, Mengod G, Cortes R. Autoradiographic localization of benzodiazepine receptors in the human brain post-mortem. In:  Biegon A,  Volkow ND editor. Sites of Drug Action in the Human Brain. Boca Raton, FL: CRC Press, Inc; 1995;p. 9–28
  59. Palfreyman MG, Schechter PJ, Buckett WR, Tell GP, Koch-Weser J. The pharmacology of GABA-transaminase inhibitors. Biochem. Pharmacol. 1981;30(8):817–824
  60. Paredes RG, Agmo A. The GABAB antagonist CGP 35348 inhibits the effects of baclofen on sexual behavior and motor coordination. Brain Res. Bull. 1995;36(5):495–497
  61. Perry TL, Kish SJ, Hansen S. gamma-Vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain. J. Neurochem. 1979;32(6):1641–1645
  62. Pinnock RD. Hyperpolarizing action of baclofen on neurons in the rat substantia nigra slice. Brain Res. 1984;332:337–340
  63. Ramos A, Berton O, Mormede P, Chaouloff F. A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behav. Brain Res. 1997;85(1):57–69
  64. Roberts DC, Andrews MM. Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure. Psychopharmacology (Berlin). 1997;131(3):271–277
  65. Roberts DC, Andrews MM, Vickers GJ. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology. 1996;15(4):417–423
  66. Salamone JD, Cousins MS, Snyder BJ. Behavioral functions of nucleus accumbens dopamine: Empirical and conceptual problems with the anhedonia hypothesis. Neurosci. Biobehav. Rev. 1997;21(3):341–359
  67. Sell LA, Morris J, Beam J, Frackowiak RS, Friston KJ, Dolan RJ. Activation of reward circuitry in human opiate addicts. Eur. J. Neurosci. 1999;11(3):1042–1048
  68. Shoaib M, Swanner LS, Beyer CE, Goldberg SR, Schindler CW. The GABAB agonist baclofen modifies cocaine self-administration in rats. Behav. Pharmacol. 1998;9(3):195–206
  69. Smith BR, Robidoux J, Amit Z. GABAergic involvement in the acquisition of voluntary ethanol intake in laboratory rats. Alcohol Alcohol. 1992;27(3):227–231
  70. Smith BR, Boyle AE, Amit Z. The effects of the GABA(B) agonist baclofen on the temporal and structural characteristics of ethanol intake. Alcohol. 1999;17(3):231–240
  71. Tidey JW, Miczek KA. Acquisition of cocaine self-administration after social stress: role of accumbens dopamine. Psychopharmacology (Berlin). 1997;130(3):203–212
  72. Turgeon SM, Albin RL. Pharmacology, distribution, cellular localization, and development of GABAB binding in rodent cerebellum. Neuroscience. 1993;55:311–323
  73. Wegelius K, Halonen T, Korpi ER. Gamma-vinyl GABA decreases voluntary alcohol consumption in alcohol-preferring AA rats. Pharmacol. Toxicol. 1993;73(3):150–152
  74. Willick ML, Kokkinidis L. The effects of ventral tegmental administration of GABAA, GABAB and NMDA receptor agonists on medial forebrain bundle self-stimulation. Behav. Brain Res. 1995;70:31–36
  75. Wise RA. Neural mechanisms of the reinforcing action of cocaine. NIDA Res. Monogr. 1984;50:15–33
  76. Wise RA, Newton P, Leeb K, Bumette B, Pocock D, Justice JB. Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology (Berlin). 1995;120(1):10–20
  77. Xi ZX, Stein EA. Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J. Pharmacol. Exp. Ther. 1999;290(3):1369–1374
  78. Xi ZX, Gorsling GJ, Tang J, Stein EA. Effects of GABA-transaminase inhibitors and GABA uptake inhibitors on heroin self-administration. Soc. Neurosci. Abstr. 1999;25:558
  79. Yan QS. Extracellular dopamine and serotonin after ethanol monitored with 5-minute microdialysis. Alcohol. 1999;19(1):1–7
  80. Yokel RA, Wise RA. Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science. 1975;187(4176):547–549
  81. Zarrindast MR, Hosseini-Nia T, Allali-Maddadi S. Food intake suppressant effect of baclofen in rats. Gen. Pharmacol. 1989;20(5):701–703

PII: S0376-8716(01)00163-6

doi: 10.1016/S0376-8716(01)00163-6

Drug and Alcohol Dependence
Volume 65, Issue 3 , Pages 209-220 , 1 February 2002

Article Tools

* Image Usage & Resolution